Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | DUT | P33316 | 10/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2990980 | 0.85 | L3MBTL1 (0.53) | CRBNPKML3MBTL1ALDH1A1LMNA | |
| SCHEMBL4348697 | 0.84 | L3MBTL1 (0.59) | CRBNPKML3MBTL1ALDH1A1LMNA | |
| SCHEMBL10924758 | 0.84 | PKM (0.55) | CRBNPKML3MBTL1ALDH1A1LMNA | |
| SCHEMBL4957852 | 0.82 | DUT (0.55) | CRBNPKML3MBTL1DUT | |
| SCHEMBL3235869 | 0.81 | L3MBTL1 (0.53) | CRBNPKML3MBTL1ALDH1A1LMNA | |
| SCHEMBL913298 | 0.81 | DUT (0.56) | CRBNPKML3MBTL1DUT | |
| SCHEMBL912535 | 0.81 | DUT (0.55) | CRBNL3MBTL1DUT | |
| SCHEMBL8377765 | 0.80 | PKM (0.51) | CRBNPKML3MBTL1ALDH1A1LMNA | |
| SCHEMBL4372127 | 0.80 | PKM (0.51) | CRBNPKML3MBTL1ALDH1A1LMNA | |
| SCHEMBL7203159 | 0.80 | PKM (0.51) | CRBNPKML3MBTL1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5830867-A | Hemoregulatory peptides for stimulating the myelopoietic system | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-03 | — | — | US | claimed |
| EP-0701446-A4 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1997-04-23 | — | — | EP | claimed |
| EP-0701446-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-20 | — | — | EP | claimed |
| WO-1994027627-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | claimed |
| US-12545712-B2 | C3d cellular and acellular vaccines for the prevention and treatment of cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250382612-A1 | COMPOSITIONS AND METHODS FOR TREATING DISEASES ASSOCIATED WITH PATHOGENIC FUS VARIANTS | THE PERRON INSTITUTE FOR NEUROLOGICAL AND TRANSLATIONAL SCIENCE LIMITED (AU) | 2025-12-18 | — | — | US | disclosed |
| US-12234448-B2 | Purification of nucleic acids using titanium oxides | ABBOTT MOLECULAR INC. | 2025-02-25 | — | — | US | disclosed |
| US-20230193240-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | ABBOTT MOLECULAR INC. | 2023-06-22 | — | — | US | disclosed |
| US-11608496-B2 | Purification of nucleic acids using copper-titanium oxides | ABBOTT MOLECULAR INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-20220242924-A1 | C3D CELLULAR AND ACELLULAR VACCINES FOR THE PREVENTION AND TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-08-04 | — | — | US | disclosed |
| EP-3988658-A1 | PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES | Abbott Molecular Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11313001-B2 | Compositions and methods for detection of microorganisms | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| WO-1999026960-A2 | GENES ENCODING FRIZZLED-LIKE PROTEINS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999024610-A1 | NOVEL GENES ENCODING TRANSPORTER-LIKE MOLECULES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 1999-05-20 | — | — | WO | disclosed |
| WO-1999007850-A1 | TANGO-71, TANGO-73, TANGO-74, TANGO-76, AND TANGO-83 NUCLEIC ACID MOLECULES AND POLYPEPTIDES | MILLENNIUM BIOTHERAPEUTICS, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1999002545-A2 | ANTIGEN BINDING FRAGMENTS, DESIGNATED 4B5, THAT SPECIFICALLY DETECT CANCER CELLS, NUCLEOTIDES ENCODING THE FRAGMENTS, AND USE THEREOF FOR THE PROPHYLAXIS AND DETECTION OF CANCERS | NOVOPHARM BIOTECH INC. (CA) | 1999-01-21 | — | — | WO | disclosed |
| US-5830867-A | Hemoregulatory peptides for stimulating the myelopoietic system | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0701446-A4 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORP (US) | 1997-04-23 | — | — | EP | disclosed |
| EP-0701446-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994027627-A1 | HEMOREGULATORY PEPTIDES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545712-B2 | C3d cellular and acellular vaccines for the prevention and treatment of cancer | C5AR2, C3AR1, CFD | CRBN 690/4885PKM 2694/4885L3MBTL1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.